Sharpkil Plus 250/62.5 Tablet: Each tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 250 mg and diluted Potassium Clavulanate BP equivalent to Clavulanic Acid 62.5 mg.
Sharpkil Plus 500/125 Tablet: Each tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 500 mg and diluted Potassium Clavulanate BP equivalent to Clavulanic Acid 125 mg.
Sharpkil Plus PFS 70 ml: After reconstitution each 5 ml suspension contains Cefuroxime 125 mg as Cefuroxime Axetil USP and Clavulanic Acid 31.25 mg as diluted Potassium Clavulanate BP.
Cefuroxime is one of the bactericidal second generation cephalosporin antibiotics, which is active against a wide range of Gram-positive and Gram-negative susceptible organisms including many b-lactamase producing strains. It is indicated for the treatment of infections caused by sensitive bacteria. The presence of clavulanic acid in Sharpkil Plus formulations protects Cefuroxime from degradation by beta-lactamase enzymes and effectively extends the antibacterial spectrum of Cefuroxime to include many bacteria normally resistant to Cefuroxime and other cephalosporins.
Pharyngitis/tonsillitis, acute bacterial otitis media, acute bacterial maxillary sinusitis, lower respiratory tract infections including pneumonia, Staphylococcus aureus, acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis, skin and skin-structure infections, urinary tract infections, bone and joint infections, gonorrhea, uncomplicated and disseminated gonococcal infections due to neisseria gonorrhoeae in both males and females, early lyme disease, septicemia & meningitis.
a) Route of administration: Oral:
Adolescents & adults:
INFECTIONS.
DOSAGE:
DURATION.
Pharyngitis or Tonsillitis.
250 mg twice daily.
5-10 days.
Acute bacterial maxillary sinusitis.
250 mg twice daily.
10 days.
Acute bacterial exacerbation of chronic bronchitis.
250-500 mg twice daily.
10 days.
Secondary bacterial infections of acute bronchitis.
250-500 mg twice daily.
5-10 days.
Community-acquired pneumonia.
250-500 mg twice daily.
5-10 days.
Uncomplicated skin & skin-structure infections.
250-500 mg twice daily.
10 days.
MDR Typhoid fever.
500 mg twice daily.
10-14 days.
Uncomplicated urinary tract infection.
250 mg twice daily.
7-10 days.
Uncomplicated gonorrhea.
1000 mg single dose.
Lyme disease.
500 mg twice daily.
20 days.
Paediatric patients (3 months to 12 years):
INFECTIONS.
DOSAGE:
DURATION.
Pharyngitis or Tonsillitis.
20 mg/kg/day in two divided doses.
5-10 days.
Acute otitis media.
30 mg/kg/day in two divided doses.
10 days.
Acute bacterial maxillary sinusitis.
30 mg/kg/day in two divided doses.
10 days.
Community-acquired pneumonia.
30 mg/kg/day in two divided doses.
5-10 days.
MDR Typhoid fever.
30 mg/kg/day in two divided doses.
10-14 days.
Uncomplicated skin & skin-structure infections.
30 mg/kg/day in two divided doses.
10 days.
Uncomplicated urinary tract infection.
20 mg/kg/day in two divided doses.
7-10 days.
Cefuroxime and Clavulanic Acid may be administered without regard to meals.
a) With medicine: Concomitant administration of probenecid with Cefuroxime and Clavulanic Acid increases the area under the serum concentration versus time curve by 50%. Drug that reduces gastric acidity may result in a lower bioavailability of Cefuroxime and tend to cancel the effect of postprandial absorption.
b) With food & other: Sharpkil plus (cefuroxime and clavulanic) usually taken with or without food.
Direction for reconstitution of suspension:
Shake the bottle well to loosen the powder. Add 40 ml of boiled and cooled water to the dry powder of the bottle. For ease of preparation, add water to the bottle in two proportions. Shake the bottle well after each addition until all the powder is in suspension.
Note: The reconstituted suspension must be stored at 2-8°C temperature and should be used within 7 days after reconstitution. Shake the suspension well before each use. Keep the bottle tightly closed.
Overdose:
Please see the dose and administration.
Cefuroxime and Clavulanic Acid should be given with care to patients receiving concurrent treatment with potent diuretics & who have history of colitis.
Store below 30°C. Protect from light. Keep all medicines out of reach of children.